Impressive thrombocytosis evolving in a patient with a BCR-ABL positive CML in major molecular response during dasatinib treatment unmasks an additional JAK2V617F

Experimental Hematology and Oncology

Volumn 2, Issue 1, 2013, Pages

  Pastore, Friederike ^a,b   Schneider, Stephanie ^a   Christ, Oliver ^a   Hiddemann, Wolfgang ^a,b   Spiekermann, Karsten ^a,b  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b INSTITUTE OF EPIDEMIOLOGY   (Germany)

Author keywords

BCR ABL; CML; JAK2V617F; MPS

Indexed keywords

BCR ABL PROTEIN; DASATINIB; DNA; HYDROXYUREA; IMATINIB; JANUS KINASE 2; LACTATE DEHYDROGENASE;

ADULT; ARTICLE; BLOOD CELL COUNT; BONE MARROW EXAMINATION; CASE REPORT; CHROMOSOME TRANSLOCATION 22; CHROMOSOME TRANSLOCATION 9; CHRONIC MYELOID LEUKEMIA; DRUG RESPONSE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE MUTATION; GENE REARRANGEMENT; GENE TRANSLOCATION; HETEROZYGOTE; HUMAN; HUMAN TISSUE; KARYOTYPE 46,XX; LACTATE DEHYDROGENASE BLOOD LEVEL; LEUKEMIA RELAPSE; LEUKEMIA REMISSION; LEUKOCYTOSIS; MUTATIONAL ANALYSIS; MYELOPROLIFERATIVE DISORDER; POINT MUTATION; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SPLENOMEGALY; THROMBOCYTOSIS; TREATMENT DURATION; TUMOR LYSIS SYNDROME;

EID: 84978024431     PISSN: None     EISSN: 21623619     Source Type: Journal    
DOI: 10.1186/2162-3619-2-24     Document Type: Article

References (27)

1. Sokal JE, Cox EB, Baccarani M, Tura S, Gomez GA, Robertson JE, Tso CY, Braun TJ, Clarkson BD, Cervantes F. Prognostic discrimination in " good-risk" chronic granulocytic leukemia. blood 1984, 63:789-799.
2. Hasford J, Pfirrmann M, Hehlmann R, Allan NC, Baccarani M, Kluin-Nelemans JC, Alimena G, Steegmann JL, Ansari H. A new prognostic score for survival of patients with chronic myeloid leukemia treated with interferon Alfa. Writing committee for the collaborative CML prognostic factors project group. J Natl Cancer Inst 1998, 90:850-858.
3. Campbell PJ, Scott LM, Buck G, Wheatley K, East CL, Marsden JT, Duffy A, Boyd EM, Bench AJ, Scott MA, Vassiliou GS, Milligan DW, Smith SR, Erber WN, Bareford D, Wilkins BS, Reilly JT, Harrison CN, Green AR, United Kingdom Myeloproliferative Disorders Study Group, Medical Research Council Adult Leukaemia Working Party, Australasian Leukaemia and Lymphoma Group Definition of subtypes of essential thrombocythaemia and relation to polycythaemia Vera based on JAK2 V617F mutation status: a prospective study. Lancet 2005, 366:1945-1953. United Kingdom Myeloproliferative Disorders Study Group, Medical Research Council Adult Leukaemia Working Party, Australasian Leukaemia and Lymphoma Group.
4. Kralovics R, Passamonti F, Buser AS, Teo S-S, Tiedt R, Passweg JR, Tichelli A, Cazzola M, Skoda RC. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med 2005, 352:1779-1790.
5. Levine RL, Wadleigh M, Cools J, Ebert BL, Wernig G, Huntly BJP, Boggon TJ, Wlodarska I, Clark JJ, Moore S, Adelsperger J, Koo S, Lee JC, Gabriel S, Mercher T, D'Andrea A, Fröhling S, Döhner K, Marynen P, Vandenberghe P, Mesa RA, Tefferi A, Griffin JD, Eck MJ, Sellers WR, Meyerson M, Golub TR, Lee SJ, Gilliland DG. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell 2005, 7(4):387-397.
6. James C, Ugo V, Le Couédic J-P, Staerk J, Delhommeau F, Lacout C, Garçon L, Raslova H, Berger R, Bennaceur-Griscelli A, Villeval JL, Constantinescu SN, Casadevall N, Vainchenker W. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature 2005, 434(7037):1144-1148.
7. Baxter EJ, Scott LM, Campbell PJ, East C, Fourouclas N, Swanton S, Vassiliou GS, Bench AJ, Boyd EM, Curtin N, Scott M, Erber WN, Green AR. Cancer Genome Project: Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 2005, 365(9464):1054-1061.
8. Jelinek J, Oki Y, Gharibyan V, Bueso-Ramos C, Prchal JT, Verstovsek S, Beran M, Estey E, Kantarjian HM, Issa J-PJ. blood 2005, 106:3370-3373.
9. Scott LM, Campbell PJ, Baxter EJ, Todd T, Stephens P, Edkins S, Wooster R, Stratton MR, Futreal PA, Green AR. The V617F JAK2 mutation is uncommon in cancers and in myeloid malignancies other than the classic myeloproliferative disorders. blood 2005, 106:2920-2921.
10. Bocchia M, Vannucchi AM, Gozzetti A, Guglielmelli P, Poli G, Crupi R, Defina M, Bosi A, Francesco L. Insights into JAK2-V617F mutation in CML. Lancet Oncol 2007, 8:864-866.
11. Pingali SRK, Mathiason MA, Lovrich SD, Go RS. Emergence of chronic myelogenous leukemia from a background of myeloproliferative disorder: JAK2V617F as a potential risk factor for BCR-ABL translocation. Clin Lymphoma Myeloma 2009, 9:E25-E29.
12. Pieri L, Spolverini A, Scappini B, Occhini U, Birtolo S, Bosi A, Albano F, Fava C, Vannucchi AM. Concomitant occurrence of BCR-ABL and JAK2V617F mutation. blood 2011, 118:3445-3446.
13. Curtin NJ, Campbell PJ, Green AR. The Philadelphia translocation and pre-existing myeloproliferative disorders. Br J Haematol 2005, 128:734-736.
14. Jallades L, Hayette S, Tigaud I, Johnston A, Coiffier B, Magaud J-P, Ffrench M. Emergence of therapy-unrelated CML on a background of BCR-ABL-negative JAK2V617F-positive chronic idiopathic myelofibrosis. Leuk Res 2008, 32:1608-1610.
15. Tefferi A, Levitt R, Lasho TL, Knudson RA, Ketterling RP. Postimatinib therapy emergence of a new JAK2V617F clone and subsequent development of overt polycythemia vera in a patient with chronic myelogenous leukaemia. Eur J Haematol 2010, 85:86-87.
16. Inami M, Inokuchi K, Okabe M, Kosaka F, Mitamura Y, Yamaguchi H, Dan K. Polycythemia associated with the JAK2V617F mutation emerged during treatment of chronic myelogenous leukemia. Leukemia 2007, 21:1103-1104.
17. Krämer A, Reiter A, Kruth J, Erben P, Hochhaus A, Müller M, Cross NC, Jones AV, Ho AD, Hensel M. JAK2-V617F mutation in a patient with Philadelphia-chromosome-positive chronic myeloid leukaemia. Lancet Oncol 2007, 8(7):658-660.
18. Nadali F, Ferdowsi S, Karimzadeh P, Chahardouli B, Einollahi N, Mousavi SA, Bahar B, Dargahi H, Alimoghaddam K, Ghavamzadeh A, Ghaffari SH. JAK2-V617F Mutation and Philadelphia Positive Chronic Myeloid Leukemia. IJHOSCR 2009, 3(3):43-45.
19. Hussein K, Bock O, Seegers A, Flasshove M, Henneke F, Buesche G, Kreipe HH. Myelofibrosis evolving during Imatinib treatment of a chronic myeloproliferative disease with coexisting BCR-ABL translocation and JAK2V617F mutation. blood 2007, 109:4106-4107.
20. Pahore Z-A-A, Shamsi TS, Taj M, Farzana T, Ansari SH, Nadeem M, Ahmad M, Naz A. JAK2V617F mutation in chronic myeloid leukemia predicts early disease progression. J Coll Physicians Surg Pak 2011, 21:472-475.
21. Nadali F, Sh F, Karimzadeh P, Chahardouli B. JAK2-V617F Mutation and Philadelphia positive chronic myeloid leukemia. IJHOSCR 2009, 3(3):43-45.
22. Tefferi A, Lasho TL, Patnaik MM, Finke CM, Hussein K, Hogan WJ, Elliott MA, Litzow MR, Hanson CA, Pardanani A. JAK2 Germline genetic variation affects disease susceptibility in primary myelofibrosis regardless of V617F mutational status: nullizygosity for the JAK2 46/1 haplotype is associated with inferior survival. Leuk 2010, 24:105-109.
23. Schaub FX, Jäger R, Looser R, Hao-Shen H, Hermouet S, Girodon F, Tichelli A, Gisslinger H, Kralovics R, Skoda RC. Clonal analysis of deletions on chromosome 20q and JAK2-V617F in MPD suggests that del20q acts independently and is not one of the predisposing mutations for JAK2-V617F. blood 2009, 113:2022-2027.
24. Schaub FX, Looser R, Li S, Hao-Shen H, Lehmann T, Tichelli A, Skoda RC. Clonal analysis of TET2 and JAK2 mutations suggests that TET2 can be a late event in the progression of myeloproliferative neoplasms. blood 2010, 115:2003-2007.
25. Bumm T, Müller C, Al-Ali H-K, Krohn K, Shepherd P, Schmidt E, Leiblein S, Franke C, Hennig E, Friedrich T, Krahl R, Niederwieser D, Deininger MWN. Emergence of clonal cytogenetic abnormalities in Ph- cells in some CML patients in cytogenetic remission to imatinib but restoration of polyclonal hematopoiesis in the majority. blood 2003, 101:1941-1949.
26. Lacout C, Pisani DF, Tulliez M, Gachelin FM, Vainchenker W, Villeval J-L. JAK2V617F expression in murine hematopoietic cells leads to MPD mimicking human PV with secondary myelofibrosis. blood 2006, 108:1652-1660.
27. Tefferi A, Pardanani A. Mutation screening for JAK2V617F: when to order the test and how to interpret the results. Leuk Res 2006, 30:739-744.